portrazza
eli lilly nederland b.v. - nécitumumab - carcinome, poumon non à petites cellules - agents antinéoplasiques - portrazza en combinaison avec la chimiothérapie par gemcitabine et cisplatine est indiqué pour le traitement des patients adultes avec récepteur localement avancé ou métastatique facteur de croissance épidermique (egfr) exprimant le cancer du poumon carcinome non à petites cellules qui n’ont pas reçu de chimiothérapie préalable pour cette condition.
abasaglar kwikpen 100 u/ml solution injectable
eli lilly (suisse) sa - insulinum glarginum - solution injectable - insulinum glarginum 3.64 mg corresp. insulinum glarginum 100 u., glycerolum, zinci oxidum, acidum hydrochloridum dilutum, natrii hydroxidum corresp. natrium 0.04 mg, metacresolum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - diabète sucré - biotechnologika
glucagon ampoule 666 1mg poudre pour solution
eli lilly and company limited - glucagon (chlorhydrate de glucagon) - poudre pour solution - 1mg - glucagon (chlorhydrate de glucagon) 1mg - glycogenolytic agents
iletin insulin regular 100unit/ml liquide
eli lilly and company limited - insuline zinc - liquide - 100unité - insuline zinc 100unité - insulins
iletin nph insulin 100unit/ml liquide
eli lilly and company limited - insulin isophane (nph) - liquide - 100unité - insulin isophane (nph) 100unité - insulins
iletin lente insulin inj 100unit/ml suspension lente
eli lilly and company limited - insuline zinc - suspension lente - 100unité - insuline zinc 100unité - insulins
nph purified pork insulin inj liquide
eli lilly and company limited - insulin isophane nph porcine - liquide - 100unité - insulin isophane nph porcine 100unité - insulins
regular purified pork insulin inj liquide
eli lilly and company limited - insuline (porcine) - liquide - 100unité - insuline (porcine) 100unité - insulins
lente purified pork insulin inj suspension lente
eli lilly and company limited - insuline - suspension lente - 100unité - insuline 100unité - insulins
verzenios
eli lilly nederland b.v. - abemaciclib - néoplasmes du sein - agents antinéoplasiques - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.